

# Leqvio® (Inclisiran)

Referring Provider Order Form – For Use with Participating Infusion Centers Rev. 7/2023

Please send completed referral form & all required documents to [referrals@healix.net](mailto:referrals@healix.net) or fax to **281-295-4086**



## PATIENT DEMOGRAPHICS

Patient Name: \_\_\_\_\_ DOB: \_\_\_\_\_ Phone: \_\_\_\_\_  
Address: \_\_\_\_\_ City/ST/Zip: \_\_\_\_\_  
Allergies: \_\_\_\_\_  NKDA Weight: \_\_\_\_\_  lbs  kg Height \_\_\_\_\_  in  cm

**INSURANCE INFORMATION: Please attach copy of insurance card (front and back).**

## DIAGNOSIS\*

**\*ICD 10 Code  
Required**

- |   |   |
|---|---|
| <input type="checkbox"/> E78.2 Mixed hyperlipidemia               | <input type="checkbox"/> E78.01 Familial Hypercholesterolemia (HeFH)  |
| <input type="checkbox"/> E78.41 Elevated Lipoprotein(a)           | <input type="checkbox"/> I25.10 Atherosclerotic Heart Disease (ASCVD) |
| <input type="checkbox"/> E78.49 Other hyperlipidemia              |   |
| <input type="checkbox"/> E78.5 Hyperlipidemia, unspecified        | <input type="checkbox"/> Other: _____, ICD10 _____                    |
| <input type="checkbox"/> E78.9 Disorder of lipoprotein metabolism |   |

## INFUSION ORDERS

MEDICATION	DOSE	DIRECTIONS/DURATION
Leqvio®(Inclisiran)	284 mg	<b>INITIAL:</b> <input type="checkbox"/> First dose: Inject SubQ x 1 dose. <input type="checkbox"/> Second dose at 3 months: Inject SubQ x 1 dose. <b>MAINTENANCE:</b> <input type="checkbox"/> Inject SubQ every 6 months x 1 year.

**Is patient currently receiving therapy above from another facility?**

NO  YES

If yes, Facility Name: \_\_\_\_\_

Date of last treatment: \_\_\_\_\_ Date of next treatment: \_\_\_\_\_

## PRE-MEDICATION ORDERS

- No premeds ordered at this time  
 Acetaminophen 650mg PO  Other: \_\_\_\_\_  
 Diphenhydramine 25mg PO

## LAB ORDERS

- Labs to be drawn by:**  Infusion Center  Referring Physician  
 No labs ordered at this time  Other: \_\_\_\_\_  
 LDL-C q \_\_\_\_\_  Lipid Panel q \_\_\_\_\_  LFTs q \_\_\_\_\_

## REFERRING PHYSICIAN INFORMATION

Physician Signature: \_\_\_\_\_ Date: \_\_\_\_\_

Physician Name: \_\_\_\_\_ Provider NPI: \_\_\_\_\_ Specialty: \_\_\_\_\_

Address: \_\_\_\_\_ City/ST/Zip: \_\_\_\_\_

Contact Person: \_\_\_\_\_ Phone #: \_\_\_\_\_ Fax #: \_\_\_\_\_

Email Where Follow Up Documentation Should Be Sent: \_\_\_\_\_

## REQUIRED CLINICAL DOCUMENTATION

**Please attach medical records: Initial H&P, current MD progress notes, medication list, and labs/test results to support diagnosis.**

For all diagnoses:

- Yes  No Is the patient's LDL-C level elevated despite treatment with maximally tolerated statin therapy?  
• Recent LDL-C level: \_\_\_\_\_ mg/dL; Date lab drawn: \_\_\_\_\_ (**Attach copy of labwork**)
- Yes  No Is the patient currently on statin therapy?  
Current statin therapy; Drug name: \_\_\_\_\_ Dosage: \_\_\_\_\_ Start date or Length of Therapy: \_\_\_\_\_  
 Check box if patient is on Zetia® (ezetimibe) in addition to statin therapy.
- If No, please specify:  Patient is statin intolerant (list failed statin therapies and reasons below)  
 Patient has a contraindication for statin therapy, specify: \_\_\_\_\_  
 Other: \_\_\_\_\_

Yes  No Has the patient been compliant with lipid lowering drug therapy and lifestyle modifications?

For ASCVD only:

History of clinical atherosclerotic cardiovascular disease includes one of more of the following: (**Select all that apply**)

- |  |   |  |
|--|---|--|
| <input type="checkbox"/> Acute coronary syndrome               | <input type="checkbox"/> Stable or unstable angina                    | <input type="checkbox"/> Transient ischemic attack (TIA)   |
| <input type="checkbox"/> Coronary artery disease (CAD)         | <input type="checkbox"/> Coronary or other arterial revascularization | <input type="checkbox"/> Peripheral arterial disease (PAD) |
| <input type="checkbox"/> History of myocardial infarction (MI) | <input type="checkbox"/> Stroke                                       | <input type="checkbox"/> Other: _____                      |

For HeFH only:

HeFH confirmed by:  Mutation in LDLR, ApoB, PCSK9, or ARH adaptor protein( LDLRAP1) gene (**Attach copy of test results**)

WHO/Dutch Lipid Clinic Network Score (DLCNS); Score: \_\_\_\_\_ (**Attach copy of assessment**)

Other: \_\_\_\_\_

## LAB RESULTS (required)

- LDL cholesterol blood level

## PRIOR FAILED THERAPIES (including statins and PCSK9 inhibitors)

Medication: \_\_\_\_\_ Dates of Treatment: \_\_\_\_\_ Reason for D/C: \_\_\_\_\_

Medication: \_\_\_\_\_ Dates of Treatment: \_\_\_\_\_ Reason for D/C: \_\_\_\_\_

Medication: \_\_\_\_\_ Dates of Treatment: \_\_\_\_\_ Reason for D/C: \_\_\_\_\_

Medication: \_\_\_\_\_ Dates of Treatment: \_\_\_\_\_ Reason for D/C: \_\_\_\_\_